Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Eidos Therapeutics Inc (EIDX)

Eidos Therapeutics Inc (EIDX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Eidos Therapeutics Inc 101 MONTGOMERY STREET SUITE 2550 SAN FRANCISCO CA 94104 USA

P: 415-887-1471

Description:

Eidos Therapeutics, Inc. is a clinical stage biopharmaceutical company. It discovers and develops novel oral therapy for the treatment of diseases caused by transthyretin amyloidosis. Eidos Therapeutics, Inc. is based in San Francisco, United States.

Key Statistics

Overview:

Market Capitalization, $K 4,750,670
Shares Outstanding, K 38,873
Annual Sales, $ 26,690 K
Annual Net Income, $ -37,840 K
Last Quarter Sales, $ 130 K
Last Quarter Net Income, $ -30,180 K
60-Month Beta -0.16
% of Insider Shareholders 71.60%
% of Institutional Shareholders 31.40%
Float, K 11,040
% Float 28.40%

Growth:

1-Year Return 125.65%
3-Year Return 0.00%
5-Year Return 0.00%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 0.00%
5-Year Dividend Growth 0.00%

Per-Share Information:

Next Earnings Date 02/24/21
Earnings Per Share ttm -2.65
EPS Growth vs. Prev Qtr -5.33%
EPS Growth vs. Prev Year -538.89%
Annual Dividend Rate, $ 0.00
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

EIDX Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward -4.56
Price/Earnings to Growth N/A
Return-on-Equity % -65.21%
Return-on-Assets % -53.04%
Profit Margin % -141.78
Net Margin % N/A
Debt/Equity 0.14
Price/Sales 36,543.62
Price/Cash Flow N/A
Price/Book 38.46
Book Value/Share 3.18
Interest Coverage -113.67
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar